Welgene Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
March 14, 2021 at 01:50 pm EDT
Share
Welgene Biotech Co.,Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was TWD 398.096 million compared to TWD 417.459 million a year ago. Operating income was TWD 35.556 million compared to TWD 38.399 million a year ago. Net income was TWD 29.774 million compared to TWD 30.871 million a year ago. Basic earnings per share was TWD 1.44 compared to TWD 1.49 a year ago. Diluted earnings per share was TWD 1.43 compared to TWD 1.48 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.
WELGENE BIOTECH CO.,LTD. 
